Answers are grounded in this paper and cite their sources.
Multiple myeloma (MM) is a clonal plasma cell disorder whose prognosis is driven by the presence or absence of a wide gamut of primary (trisomies and translocations) and secondary (monosomies/deletions and amplifications) genetic abnormalities. Translocations involving the immunoglobulin heavy chain (IgH) region on chromosome 14 and one of its partners on chromosomes 4, 6, 11, 16 and 20 occur in approximately 40% of MM patients. Among the IgH translocations, t(11;14) is the most commonly observed lesion (occurring in 16–24% of MM patients), while t(14;16) is rather uncommon (<5% of patients, in most reported series) 1 , 2 , 3 . The International Myeloma Working Group (IMWG) 4 , 5 and the m-SMART 6 risk-stratification currently consider t(11;14) as a standard-risk chromosomal abnormality 7 , hile t(4;14), t(14;16) and t(14;20) have been associated with poor survival, although the data on the prognostic impact of t(14;16) in the era of newer anti-myeloma drugs have not been extensively reported and few retrospective studies have reported conflicting results on the prognostic significance of this abnormality 1 , 8 , 9 . t(14;16)(q32;q23) involves the IgH locus and the c-musculoaponeurotic fibrosarcoma (c-MAF) oncogene locus, the latter likely being responsible, at least partially, of the MAF-mediated innate resistance to proteasome inhibition, a backbone treatment in current myeloma regimens 10 .
No takes yet. Share an insight, caveat, or question.
Mina et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: